Parkinson disease (PD) is a chronic, progressive, neurodegenerative disorder characterized by loss of dopaminergic neurons in the striata nigrum. PD is considered to be one of the most common neurological disorders and affects nearly 1% of all individuals over 60 years of age and nearly 4% of all individuals over 85 years.
PD often progresses slowly, and may, in fact, go unnoticed in its early stages. The three cardinal signs of the condition are tremor, slowing of motion (bradykinesia), and rigidity. Symptoms usually begin on one side of the body and this side remains worse affected. Other symptoms associated with this condition include impaired posture and balance, loss of automatic movements like blinking, smiling, and swinging of arms while walking, loss of fine motor skills, speech changes, muscle aches, changes in facial expression, dementia, and a decline in intellectual function. Depression, confusion, muscular atrophy, and anxiety may also be present in some patients. The underlying cause of PD is the failure of neurons in the brain to produce dopamine, a neurotransmitter. It is not clear why this impairment occurs. However, age is considered to be a major risk factor for the condition, in conjunction with certain genetic factors. PD usually occurs either in middle or late life, and its risk continues to increase with age. The incidence of PD is estimated at 4.5-21 cases per 100,000 of the population per year.
There is no definitive test for the diagnosis of PD. However, the presence of at least two of the three cardinal signs along with a strong response to externally supplied levodopa, an intermediate in dopamine biosynthesis, is considered a positive diagnosis of PD. A number of drugs are available for the management of PD. Levodopa is the most effective of these. The effects of this drug are usually dramatic in the beginning, but wane after continued usage. Other drugs include dopamine agonists, MAO B inhibitors, COMT inhibitors, and anticholinergics. None of these drugs are completely effective in curing the condition. Physical therapy may be required to improve mobility. Deep brain stimulation is a surgical intervention used in patients with an advanced stage of the disease. This technique involves implanting an electrode within the brain, controlled by an external pacemaker-like device.
In the vast majority of PD patients the disease results from a combination of mostly unknown genetic and environmental factors. Yet, approximately 15% of affected patients display a family history of the condition. In most of these families, mutation in at least one of the following genes has been implicated in the development of this condition: LRRK2 (Leucine-Rich Repeat Kinase 2), PARK2, PARK7, PINK1 (PTEN-Induced Putative Kinase 1), or SNCA (Synuclein, Alpha). Mutations in most of these genes lead to the development of PD by either interfering with the proper ubiquitination of proteins or causing excess free radical production by the mitochondria.